Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

@article{Butts2007RandomizedPI,
  title={Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.},
  author={Charles A. Butts and David J. Bodkin and Edward L. Middleman and Craig W Englund and David E. Ellison and Yasmin Alam and Harvey Kreisman and Peter Graze and James Maher and Helen J. Ross and Peter Michael Ellis and William E. Mcnulty and Edward K. Kaplan and Virginie Pautret and Weber Martin Richard and Frances A. Shepherd},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 36},
  pages={
          5777-84
        }
}
PURPOSE To evaluate the efficacy of cetuximab added to first-line gemcitabine/platinum in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS In this noncomparative, randomized trial, chemotherapy-naïve patients with recurrent/metastatic NSCLC (stage IV or stage IIIB with malignant pleural effusion) were eligible. Patients received cisplatin (75 mg/m2 i.v., every 3 weeks) or carboplatin (area under the concentration-versus-time curve of 5… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 62 CITATIONS, ESTIMATED 48% COVERAGE

Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review.

  • The Journal of community and supportive oncology
  • 2016
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Clinical meta-analyses of targeted therapies in adenocarcinoma

  • Targeted Oncology
  • 2013
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Cetuximab in non-small-cell lung cancer.

  • Translational lung cancer research
  • 2012
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Cetuximab-based Therapy is Effective in Chemotherapy-naïve Patients with Advanced and Metastatic Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

Ezzeldin M. Ibrahim, Khaled M. Abouelkhair, Osama A. Al-Masri, Najeeb C. Chaudry, Ghieth A. Kazkaz
  • Lung
  • 2011
VIEW 5 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer.

  • Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2007
2018

CITATION STATISTICS

  • 6 Highly Influenced Citations